Mr. Schor’s inducement grant consisted of 150,000 shares of restricted
common stock and an option to purchase up to 450,000 shares of common
stock. Mr. Schneebaum’s inducement grant consisted of 75,000 shares of
restricted common stock and an option to purchase up to 225,000 shares
of common stock. The restricted stock will vest as to 50% of the shares
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using its compound library and discovery capabilities. For more information, please visit www.syntapharma.com.
Synta Pharmaceuticals Corp.
Daniel Cole, (781) 541-7250
Andrea Rabney, (212) 600-1494
Eliza Schleifstein, (917) 763-8106